COLL Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Collegium Pharmaceutical (NASDAQ: COLL)
›
Collegium Pharmaceutical (NASDAQ: COLL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 423 employees.
The shares were at 25.21 USD on 19 November 2026, down 38.0% over 52 weeks. Its 52-week range is 21.43 USD to 50.79 USD: the price is 50.4% below the high and 17.6% above the low.
At a market capitalisation of 783.41M USD, it trades at 23.1 times trailing earnings and 3.6 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, so COLL is valued in line with them.
Collegium Pharmaceutical reports return on equity of 20.8%, an operating margin of 22.9% and revenue up 3.3% year over year.
Its debt exceeds its cash by 1.06B USD, a debt-to-equity ratio of 2.70. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 44.00 USD is 74.5% above the current price. The next earnings report is expected on 25 February 2027.